NasdaqGS:KPTI

Stock Analysis Report

Executive Summary

Karyopharm Therapeutics Inc., an oncology-focused pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.

Risks

  • Karyopharm Therapeutics has significant price volatility in the past 3 months.

Share Price & News

How has Karyopharm Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

2.4%

NasdaqGS:KPTI

-0.2%

US Biotechs

-1.0%

US Market


1 Year Return

-49.3%

NasdaqGS:KPTI

-8.1%

US Biotechs

-0.4%

US Market

KPTI underperformed the Biotechs industry which returned -8.1% over the past year.

KPTI underperformed the Market in United States of America which returned -0.4% over the past year.


Share holder returns

KPTIIndustryMarket
7 Day2.4%-0.2%-1.0%
30 Day9.3%-0.2%-3.3%
90 Day76.5%2.4%0.4%
1 Year-49.3%-49.3%-7.3%-8.1%1.8%-0.4%
3 Year12.3%12.3%9.7%5.9%39.4%30.4%
5 Year-75.0%-75.0%7.8%2.8%54.2%37.1%

Price Volatility Vs. Market

How volatile is Karyopharm Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Karyopharm Therapeutics undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Karyopharm Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).

Karyopharm Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Karyopharm Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.

Karyopharm Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Karyopharm Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Karyopharm Therapeutics is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Karyopharm Therapeutics expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

34.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Karyopharm Therapeutics's revenue is expected to grow significantly at over 20% yearly.

Karyopharm Therapeutics's earnings are expected to grow significantly at over 20% yearly.

Karyopharm Therapeutics's revenue growth is expected to exceed the United States of America market average.

Karyopharm Therapeutics's earnings growth is expected to exceed the United States of America market average.

Karyopharm Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Karyopharm Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Karyopharm Therapeutics performed over the past 5 years?

-19.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Karyopharm Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Karyopharm Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Karyopharm Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Karyopharm Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Karyopharm Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Karyopharm Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Karyopharm Therapeutics's financial position?


Financial Position Analysis

Karyopharm Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Karyopharm Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Karyopharm Therapeutics's level of debt (128.7%) compared to net worth is high (greater than 40%).

Unable to establish if Karyopharm Therapeutics's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.1x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Karyopharm Therapeutics has sufficient cash runway for 1.1 years based on current free cash flow.

Karyopharm Therapeutics has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 32.3% each year.


Next Steps

Dividend

What is Karyopharm Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Karyopharm Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Karyopharm Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Karyopharm Therapeutics has not reported any payouts.

Unable to verify if Karyopharm Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Karyopharm Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Karyopharm Therapeutics's salary, the management and board of directors tenure and is there insider trading?

4.6yrs

Average management tenure


CEO

Michael Kauffman (56yo)

8.6yrs

Tenure

US$2,274,945

Compensation

Dr. Michael G. Kauffman, M.D., Ph.D. serves as Advisor at Prime Movers Lab and co-founded Karyopharm Therapeutics Inc. in 2008 and has been its Chief Executive Officer since January 05, 2011. Dr. Kauffman  ...


CEO Compensation Analysis

Michael's remuneration is about average for companies of similar size in United States of America.

Michael's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

4.6yrs

Average Tenure

50yo

Average Age

The tenure for the Karyopharm Therapeutics management team is about average.


Board Age and Tenure

5.3yrs

Average Tenure

56yo

Average Age

The tenure for the Karyopharm Therapeutics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$619,11405 Mar 19
Wiaczeslaw Smolokowski
EntityIndividual
Shares149,624
Max PriceUS$4.14
SellUS$7,127,92428 Feb 19
Wiaczeslaw Smolokowski
EntityIndividual
Shares1,481,643
Max PriceUS$5.00
SellUS$3,468,73007 Sep 18
Wiaczeslaw Smolokowski
EntityIndividual
Shares164,800
Max PriceUS$21.06
SellUS$5,265,36804 Sep 18
Wiaczeslaw Smolokowski
EntityIndividual
Shares251,468
Max PriceUS$21.05
SellUS$4,178,05630 Aug 18
Wiaczeslaw Smolokowski
EntityIndividual
Shares214,026
Max PriceUS$19.59

Ownership Breakdown


Management Team

  • Michael Kauffman (56yo)

    Co-Founder

    • Tenure: 8.6yrs
    • Compensation: $2.27m
  • Mike Mason (44yo)

    Senior VP

    • Tenure: 0.5yrs
  • Chris Primiano (38yo)

    Executive VP

    • Tenure: 5.4yrs
    • Compensation: $1.52m
  • Ian Karp

    Vice President of Investor & Public Relations

    • Tenure: 1.1yrs
  • Mansoor Mirza (58yo)

    Clinical Consultant

    • Tenure: 9.6yrs
    • Compensation: $367.59k
  • Sharon Shacham (49yo)

    Co-Founder

    • Tenure: 5.7yrs
    • Compensation: $2.09m
  • Ran Frenkel (50yo)

    Chief Development Operations Officer

    • Tenure: 4.6yrs
    • Compensation: $6.48m
  • Perry Monaco

    Senior Vice President of Sales

  • Tina Beamon

    Chief Compliance Officer

    • Tenure: 0.3yrs
  • Cameron Peters (59yo)

    Vice President of Finance

    • Tenure: 0.6yrs

Board Members

  • Garen Bohlin (72yo)

    Independent Director

    • Tenure: 5.8yrs
    • Compensation: $278.59k
  • Mikael Dolsten (60yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: $266.59k
  • Michael Kauffman (56yo)

    Co-Founder

    • Tenure: 11.6yrs
    • Compensation: $2.27m
  • Barry Greene (56yo)

    Lead Independent Director

    • Tenure: 4.6yrs
    • Compensation: $312.12k
  • Mansoor Mirza (58yo)

    Clinical Consultant

    • Compensation: $367.59k
  • Sharon Shacham (49yo)

    Co-Founder

    • Compensation: $2.09m
  • J. Garland (50yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: $280.59k
  • Deepa Pakianathan (54yo)

    Independent Director

    • Tenure: 6.3yrs
    • Compensation: $274.37k
  • Chris Kirk (47yo)

    Member of Scientific Advisory Board

  • Giulio Draetta

    Chairman of Scientific Advisory Board

Company Information

Karyopharm Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Karyopharm Therapeutics Inc.
  • Ticker: KPTI
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: biotechnology
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$561.619m
  • Shares outstanding: 61.92m
  • Website: Click here

Number of Employees


Location

  • Karyopharm Therapeutics Inc.
  • 85 Wells Avenue
  • 2nd Floor
  • Newton
  • Massachusetts
  • 2459
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
KPTINasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2013
25KDB (Deutsche Boerse AG)YesCommon StockDEEURNov 2013

Biography

Karyopharm Therapeutics Inc., an oncology-focused pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets f ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/18 00:55
End of Day Share Price2019/08/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.